Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AWP Litigation Increases As Justice Dept. Sues Roxane For Price Inflation

  • News

Executive Summary

Another lawsuit has been added to the tangle of litigation over average wholesale drug pricing

You may also be interested in...



AWP Litigation: Three More Companies Ink Deals With DoJ; Roxane Sets A Record

The heavy docket of average wholesale price cases got a bit lighter as three pharma companies agreed to pay $421 million to settle claims they inflated the AWP of numerous drugs, thus increasing reimbursement levels.

AWP Litigation: Three More Companies Ink Deals With DoJ; Roxane Sets A Record

The heavy docket of average wholesale price cases got a bit lighter as three pharma companies agreed to pay $421 million to settle claims they inflated the AWP of numerous drugs, thus increasing reimbursement levels.

AWP Litigation Takes New Twist As Abbott Seeks Sanctions Against DoJ

Abbott is pursuing a new tactic in litigation over its average wholesale drug pricing. It is accusing the Department of Justice of failing to preserve evidence critical to its defense

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS048013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By